N/A N=1 Evaluate Health Coaching Support in Technology-based Interventions for Meeting Health Goals
Chronic Disease Prevention
Primary: Self-efficacy: Healthful Eating Via Revised Eating Self-Efficacy Scale (ESES-R) — 2.3 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=33 Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes With AID Use
Type 1 Diabetes
Primary: Severe Hypoglycemic Events — 0; 0.06 number of events
N/A N=13 ASSURE WCD Clinical Evaluation - Conversion Efficacy Study
Death, Sudden, Cardiac
Primary: Cumulative First and Second Shock VT/VF Conversion Rate — 100; 100 percentage
N/A N=1,388 Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.
Influenza, Human
Primary: Number of Participants With Expected Adverse Events (AEs) — 54; 44 Participants
Phase 4 N=12 Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children
Influenza Vaccines
Primary: Type-specific Vaccine Virus Shedding in 2018/19 - Day 1 Post LAIV — 3 Participants
N/A N=1,187 Telecommunication Enhanced Asthma Management
Asthma
Primary: Medication Adherence — .445; .355 Proportion of Days Covered
Early Phase 1 N=48 A Mind Body Intervention to Reduce Symptoms Among People Aging With HIV
Mental Health · Physical Health
Primary: Acceptability: Satisfaction With Weekly Intervention Sessions — 13; 12; 0; 12 Participants
N/A N=99 Effects of Walking and Heating on Vascular Function in Diabetic Patients
Type 2 Diabetes Mellitus · Obesity
Primary: Insulin-stimulated Leg Blood Flow Calculated as Percent Change (t0, t60) — 133.6; 8.92 percentage change
N/A N=76 Stress and Sleep Study
Stress, Psychological · Sleep · Transcutaneous Electric Nerve Stimulation
Primary: Acceptability of the Combined tVNS + Mindfulness Intervention as Assessed by Participant Self-report of Acceptability Using the Acceptability of Intervention Measure…
N/A N=75 Translating an Efficacious Illness Management Intervention for Youth With Asthma
Asthma in Children
Primary: Number of Emergency Department Visits — 0.67; 0.68; 0.28; 0.50 Count of ED visits in prior six months — p=0.43
N/A N=100 Caregiving During Crisis
Caregiver Stress Syndrome
Primary: Center for Epidemiologic Studies - Depression (CES-D) Scale Score — 11.7; 11.8; 10.4; 14.6 score on a scale
N/A N=60 Comparing a Fatherhood Focused Individual Intervention to Batterer Intervention to Reduce IPV and Child Maltreatment
Intimate Partner Violence
Primary: Completion Rate — 20; 21 Participants
N/A N=5,044 Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
Coronavirus Disease 2019 (COVID-19)
Primary: All-cause Mortality — 40; 671 Person-trials
Phase 3 N=248 An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
Neovascular Age-related Macular Degeneration
Primary: Duration of the Last Interval With no Disease Activity up to Week 56 - Study Eye — 68; 59; 47; 49 Participants
Phase 3 N=1,004 A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Urinary Tract Cancer
Primary: Percentage of Participants With Adverse Events (AEs) — 900 Participants